Abstract
In the previous report , we described the discovery and optimization of novel small molecule disruptors of the GK-GKRP interaction culminating in the identification of 1 (AMG-1694). Although this analogue possessed excellent in vitro potency and was a useful tool compound in initial proof-of-concept experiments, high metabolic turnover limited its advancement. Guided by a combination of metabolite identification and structure-based design, we have successfully discovered a potent and metabolically stable GK-GKRP disruptor (27, AMG-3969). When administered to db/db mice, this compound demonstrated a robust pharmacodynamic response (GK translocation) as well as statistically significant dose-dependent reductions in fed blood glucose levels.
MeSH terms
-
Alkynes / chemical synthesis
-
Alkynes / pharmacokinetics
-
Alkynes / pharmacology
-
Animals
-
Blood Glucose / metabolism
-
Carrier Proteins / chemistry
-
Carrier Proteins / metabolism*
-
Glucokinase / chemistry
-
Glucokinase / metabolism*
-
Hepatocytes / drug effects
-
Hepatocytes / metabolism
-
Humans
-
Hypoglycemic Agents / chemistry*
-
Hypoglycemic Agents / pharmacokinetics
-
Hypoglycemic Agents / pharmacology
-
Mice
-
Microsomes, Liver / metabolism
-
Models, Molecular
-
Morpholines / chemical synthesis
-
Morpholines / pharmacokinetics
-
Morpholines / pharmacology
-
Piperazines / chemical synthesis*
-
Piperazines / pharmacokinetics
-
Piperazines / pharmacology
-
Protein Binding
-
Protein Transport
-
Rats
-
Stereoisomerism
-
Structure-Activity Relationship
-
Sulfonamides / chemical synthesis*
-
Sulfonamides / pharmacokinetics
-
Sulfonamides / pharmacology
Substances
-
2-(4-(4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol
-
Alkynes
-
Blood Glucose
-
Carrier Proteins
-
Hypoglycemic Agents
-
Morpholines
-
Piperazines
-
Sulfonamides
-
glucokinase regulatory protein
-
Glucokinase